Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est

Benzinga Newsdesk www.benzinga.com Negative 76.2%

Neg 76.2% Neu 0% Pos 0%

Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2026 sales outlook from $840.000 million-$870.000 million to $840.000 million-$870.000 million vs $862.242 million estimate.